{"id":"NCT03126435","sponsor":"SynCore Biotechnology Co., Ltd.","briefTitle":"EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX","officialTitle":"A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-16","primaryCompletion":"2021-07-30","completion":"2021-10-08","firstPosted":"2017-04-24","resultsPosted":"2023-03-24","lastUpdate":"2023-05-06"},"enrollment":218,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Pancreas Cancer","Locally Advanced Pancreatic Cancer","Pancreatic Adenocarcinoma"],"interventions":[{"type":"DRUG","name":"EndoTAG-1","otherNames":["EndoTAG-1 was first developed by Munich Biotech AG (Germany) under the names LipoPac and MBT-0206 and by Medigene AG under the name of EndoTAG-1."]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemcitabine Hydrochloride"]}],"arms":[{"label":"EndoTAG-1 and Gemcitabine","type":"EXPERIMENTAL"},{"label":"Gemcitabine Monotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From randomization to death from any cause or last day known to be alive, up to approximately 33.5 months (assessed continuously during treatment)","effectByArm":[{"arm":"EndoTAG-1 and Gemcitabine","deltaMin":226,"sd":null},{"arm":"Gemcitabine Monotherapy","deltaMin":209,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6647"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":68,"countries":["United States","France","Hungary","Israel","Russia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":102},"commonTop":["Platelet Count Decreased","Decreased Appetite","Constipation","Neutrophil Count Decreased","White Blood Cell Count Decreased"]}}